

Ensuring Diversity in a COVID-19 Study.

Accelerating access to patients in underserved communities and a diverse population

Situation

Enabling **rapid response** to a public health crisis

The non-profit sponsor, conducting a study evaluating the safety and efficacy of a prescription blood thinner, aimed to more quickly realize if the intervention was effective for high-risk patients with mild COVID-19. Science 37 offered a flexible approach to quickly access a more representative patient population.

Solution

Decentralization for a more **representative patient population**

Utilizing the Science 37 Operating System™, underpinned by our end-to-end technology platform and specialized networks, we were able to tap into our Global Healthcare Provider Network to identify sites that could enroll patients via high-recruiting providers utilizing targeted, digital outreach strategies, telemedicine, and direct-to-patient study supplies.

Impact

Greater **diversity and pivoting** the study

By leveraging our Operating System and activating our virtual study arm (known as Metasite™) to supplement a network of traditional sites, the sponsor was able to access high-risk patients, typically underserved by clinical trials, without geographic boundaries, and more quickly realize the intervention's ineffectiveness and re-prioritize efforts on more viable treatment options.

- Facilitating enrollment of 90% of the target population in five months
- Enabling a more representative patient population of 27% non-white patients by the end of the trial

“What was really a good learning is that every specific population needs representation in clinical trials. And I think that’s a field that will evolve significantly after COVID.”

– Sponsor



Our bespoke approach to every trial

We take a bespoke approach to all our trials. We understand every therapeutic area is different and perform careful review of trial design, inclusion/exclusion criteria, and review of the specific needs and/or study participation challenges expressed from diverse patients and providers to do our part to reduce barriers and support clinical trial equity.

Let's Talk.

Please contact us at diversityinnovation@science37.com to learn more about how we do Diversity in Clinical Trials.

About Science 37

Science 37 accelerates clinical research by enabling universal access to patients and providers, anywhere. The Science 37 Operating System™—underpinned by an end-to-end technology platform and supported by specialized networks to enable trial orchestration—enables up to 15x faster trial enrollment, 28% greater patient retention and 3x more diversity. Science 37 and its Operating System can be configured to conduct the full clinical trial, act as a virtual site (known as Metasite™) or deploy its technology in combination with any of its specialized networks to enable flexibility across nearly any study design. Founded in 2014 as a pioneer in decentralized clinical trials, Science 37 has conducted more fully decentralized, interventional clinical trials than any other provider and has the most complete Operating System.

CONTACT US

diversityinnovation@science37.com
science37.com

